EQS-Adhoc
113 
0 Kommentare
PharmaSGP Holding SE: Peter Gerckens succeeds Natalie Weigand as Chief Executive Officer
- Peter Gerckens appointed CEO, effective January 1, 2025.
- Natalie Weigand will not extend her contract, stepping down.
- Weigand to remain in an advisory role post-departure.
|
EQS-Ad-hoc: PharmaSGP Holding SE / Key word(s): Personnel PharmaSGP Holding SE: Peter Gerckens succeeds Natalie Weigand as Chief Executive Officer |
Gräfelfing, November 05, 2024 – Peter Gerckens, who has been a member of the Management Board of PharmaSGP Holding SE as Chief Commercial Officer (CCO) since July 1, 2024, will take over the position of Chief Executive Officer (CEO) of the company on January 1, 2025. This was decided by the Supervisory Board today. Peter Gerckens succeeds Natalie Weigand in this position. She informed the Supervisory Board today that she has decided not to extend her contract, which expires at the end of the year. However, Natalie Weigand will remain associated with the company in an advisory role after her departure.
* * *
Contact
PharmaSGP Holding SE
Claudius Krause | Jakob Hafer (cometis AG)
Lochhamer Schlag 1
82166 Gräfelfing | Germany
Phone: +49 611 205855-0
E-Mail: ir@pharmasgp.com
End of Inside Information
05-Nov-2024 CET/CEST The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.eqs-news.com
| Language: | English |
| Company: | PharmaSGP Holding SE |
| Lochhamer Schlag 1 | |
| 82166 Gräfelfing | |
| Germany | |
| E-mail: | ir@pharmasgp.com |
| Internet: | https://pharmasgp.com |
| ISIN: | DE000A2P4LJ5 |
| WKN: | A2P4LJ |
| Listed: | Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Munich, Tradegate Exchange |
| EQS News ID: | 2022283 |
| End of Announcement | EQS News Service |
|
|
2022283 05-Nov-2024 CET/CEST
Diskutieren Sie über die enthaltenen Werte
URL kopieren
Per E-Mail teilen
Artikel drucken